Background Ovarian cancer (OC) is the most lethal gynecologic malignancy worldwide. One
of the main challenges in the management of OC is the late clinical presentation of disease …

An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …

Liquid biopsies hold the potential to inform cancer patient prognosis and to guide treatment
decisions at the time when direct tumor biopsy may be impractical due to its invasive nature …

Highlights•Cell-free nucleic acids in body fluids contain tumour fragments that can be
profiled for prognostic and diagnostic information for the management of cancer.•cfDNA …

Purpose: Neuroblastoma (NB) is a heterogeneous disease characterized by distinct clinical
features and by the presence of typical copy-number alterations (CNAs). Given the strong …

Abstract The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
recently reported a reduction in the average overall mortality among ovarian cancer patients …

Precision medicine has impacted the field of medical oncology by introducing personalized
therapies, improving all measurable outcomes. This field, in turn, has expanded to obtaining …

Ovarian cancer remains the most lethal disease among gynecological malignancies despite
the plethora of research studies during the last decades. The majority of patients are …

Tissue biopsy is the standard diagnostic procedure for cancer. Biopsy may also provide
material for genoty**, which can assist in the diagnosis and selection of targeted therapies …